Inhibition of SARS-CoV-2 Omicron BA.1 and BA.4 Variants After Fourth Vaccination or Tixagevimab and Cilgavimab Administration in Patients With Cancer.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.4226
Abstract: This cohort study assesses the capacity of passive immunization and tixagevimab and cilgavimab to inhibit interaction between receptor-binding domains and angiotensin-converting enzyme 2 in patients with hemato-oncologic diseases. read more here.
Keywords: tixagevimab; inhibition sars; tixagevimab cilgavimab; omicron variants ... See more keywords
Efficacy and safety of tixagevimab‐cilgavimab as pre‐exposure prophylaxis for COVID‐19: A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2023 at "Reviews in Medical Virology"
DOI: 10.1002/rmv.2420
Abstract: Some proportions of populations, such as immunocompromised patients and organ transplant recipients might have inadequate immune responses to the vaccine for coronavirus disease 2019 (COVID‐19). For these groups of populations, administering monoclonal antibodies might offer… read more here.
Keywords: review; covid; tixagevimab cilgavimab; analysis ... See more keywords
Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac283
Abstract: Abstract Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the… read more here.
Keywords: severe acute; coronavirus; tixagevimab cilgavimab; cilgavimab ... See more keywords
Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients
Sign Up to like & getrecommendations! Published in 2022 at "Rheumatology"
DOI: 10.1101/2022.11.07.22281786
Abstract: Background and aims Immunocompromised patients have a reduced ability to generate antibodies after COVID-19 vaccination and are at higher risk of SARS-CoV-2 infection, complications and mortality. Tixagevimab/Cilgavimab (Evusheld) is a monoclonal antibody combination which bind… read more here.
Keywords: clinical effectiveness; covid; tixagevimab cilgavimab; immunocompromised patients ... See more keywords
Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Transplantation"
DOI: 10.1111/ajt.17128
Abstract: The neutralizing monoclonal antibody combination of tixagevimab/cilgavimab has been shown to reduce the risk of SARS‐CoV‐2 infection in unvaccinated individuals during the Alpha (B.1.1.7) and Delta (B.1.617.2) waves. However, data on the efficacy and safety… read more here.
Keywords: tixagevimab cilgavimab; organ transplant; solid organ; transplant recipients ... See more keywords
Patient‐reported outcomes after Tixagevimab and Cilgavimab pre‐exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk
Sign Up to like & getrecommendations! Published in 2023 at "Clinical Transplantation"
DOI: 10.1111/ctr.14913
Abstract: Tixagevimab and Cilgavimab (T + C) is authorized for pre‐exposure prophylaxis (PrEP) against Coronavirus Disease 2019 (COVID‐19) in solid organ transplant recipients (SOTRs), yet patient‐reported outcomes after injection are not well described. Furthermore, changes in… read more here.
Keywords: exposure prophylaxis; tixagevimab cilgavimab; pre exposure; transplant recipients ... See more keywords
Tixagevimab-Cilgavimab: COVID-19 Pre-Exposure Prophylaxis.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical journal of oncology nursing"
DOI: 10.1188/22.cjon.479-482
Abstract: Tixagevimab-cilgavimab is the only nonvaccine drug currently authorized in the United States for the prevention of COVID-19 infection in individuals who are moderately to severely immunocompromised or unable to receive COVI. read more here.
Keywords: cilgavimab covid; exposure prophylaxis; tixagevimab cilgavimab; cilgavimab ... See more keywords
Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
Sign Up to like & getrecommendations! Published in 2022 at "PLOS ONE"
DOI: 10.1371/journal.pone.0275356
Abstract: Background: Pre-exposure prophylaxis for COVID-19 with tixagevimab/cilgavimab (T/C) received Emergency Use Authorization (EUA) based off of results from a clinical trial conducted prior to the Omicron variant. Its clinical effectiveness has not been well described… read more here.
Keywords: omicron era; covid; tixagevimab cilgavimab; effectiveness ... See more keywords
Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1139980
Abstract: Introduction The effect of tixagevimab/cilgavimab (Evusheld™; AstraZeneca, UK) should be evaluated in the context of concurrent outbreak situations. Methods For serologic investigation of tixagevimab/cilgavimab during the BA.5 outbreak period, sera of immunocompromised (IC) hosts sampled… read more here.
Keywords: tixagevimab; one month; tixagevimab cilgavimab; cilgavimab administration ... See more keywords
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1157610
Abstract: Introduction Patients with multiple myeloma (MM) frequently reported immune impairment with an increased risk for infection-related mortality. We aimed to evaluate the immune response in MM patients vaccinated for SARS-CoV-2 during active treatment. Methods We… read more here.
Keywords: tixagevimab cilgavimab; prophylaxis tixagevimab; response; sars cov ... See more keywords
Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience
Sign Up to like & getrecommendations! Published in 2022 at "Viruses"
DOI: 10.3390/v15010118
Abstract: Effective treatments and vaccines against COVID-19 used in clinical practice have made a positive impact on controlling the spread of the pandemic, where they are available. Nevertheless, even if fully vaccinated, immunocompromised patients still remain… read more here.
Keywords: cilgavimab sars; high risk; covid; tixagevimab cilgavimab ... See more keywords